New drug trial targets shrinking untreatable nerve tumors
NCT ID NCT02407405
Summary
This study is testing whether the drug selumetinib can shrink or slow the growth of large, inoperable nerve tumors (plexiform neurofibromas) in adults with Neurofibromatosis Type 1 (NF1). Participants take capsules twice daily for as long as they tolerate the drug and their disease does not progress. The goal is to see if this drug can control these difficult-to-treat tumors and improve symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS 1 (NF1) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.